Shire is discontinuing the manufacture and distribution of BEBULIN®, the company’s factor IX human plasma-derived prothrombin complex concentrate product. BEBULIN® is indicated for the prevention and control of bleeding episodes in adult patients with hemophilia B. The National Hemophilia Foundation has been notified by Shire that this decision was based on the reduced demand and is not connected with any new safety or efficacy findings in relation to the therapy.
The company also stated that it is their intent to provide enough advanced notice of the discontinuation to allow patients to transition to a suitable alternative therapy. Current available inventory is estimated to be depleted in September 2018 with an expiration date of November 30, 2018. Shire will accept orders from this inventory on a “first come, first serve” basis until stock is depleted.
The company is encouraging individuals with questions to contact Shire Customer Service at 1.800.423.2090.
